Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Sirolimus for Kaposiform Hemangioendothelioma in Children
NCT04077515Phase 4Completed
- Sponsor
- Children's Hospital of Fudan University
- Start
- May 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sirolimus in kaposiform hemangioendothelioma (KHE), sponsored by Children's Hospital of Fudan University. Primary endpoint: Response to treatment at 1 year. Started May 2019; status: completed.
02
Drugs
sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)
Beyond the preview
Go deeper on NCT04077515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04077515.